PF-Atlas › Clinical Trials › INTEGRIS-IPF

PLN-74809 Dual Integrin Inhibitor in IPF

PLN-74809 · Integrin avb6/b1 · Phase 2

Registry ID
INTEGRIS-IPF
Phase
Phase 2
Status
Active, not recruiting
Drug / intervention
PLN-74809
Mechanism
Integrin avb6/b1
Sponsor
Pliant Therapeutics
Start
2022-01

About this trial

PLN-74809 is evaluated in INTEGRIS-IPF, a Phase 2 idiopathic pulmonary fibrosis study sponsored by Pliant Therapeutics, targeting integrin avb6/b1. Current status: Active, not recruiting.

View INTEGRIS-IPF on ClinicalTrials.gov →

Explore related

PLN-74809 — Treatment profileAll PLN-74809 trialsIntegrin avb6/b1 mechanismAll IPF trials

Related trials

PLN-74809 — NCT04072315PLN-74809 — NCT04396756PLN-74809 — NCT06097260
Medical disclaimer. This page summarizes public trial data for INTEGRIS-IPF for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.